The validation results of Oncomine suggested that FOXQ1 was upregulated in colon adenocarcinoma and liver hepatocellular carcinoma and downregulated in kidney cancer and prostate adenocarcinoma, which was consistent with TCGA results (Figure 1B). Here, FOXQ1 is linked to prostate adenocarcinoma.